1887

Abstract

Respiratory syncytial virus (RSV) is one of the primary causative agents of upper and lower respiratory tract infections in young children, in particular infants. Recently, we reported the protective efficacy of a RSV vaccine formulation consisting of a truncated version of the fusion (F) protein formulated with a Toll-like receptor (TLR) agonist and an immunostimulatory peptide in a carrier system (ΔF/TriAdj). To evaluate the duration of immunity induced by this vaccine candidate, we carried out long-term trials. The ΔF was formulated with triple adjuvant (TriAdj) containing either polyinosinic : polycytidylic acid (polyI : C) or cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) and administered intranasally to mice. One year after the second vaccination all mice were challenged with RSV. Both ΔF/TriAdj formulations mediated the induction of high levels of IgG1, IgG2a and virus-neutralizing antibodies, and IgA in the lungs. Based on the numbers of IFN-γ- and IL-5-secreting cells in the spleen, the immune response was slightly T-helper cell type 1 (Th1)-biased. This was confirmed by the presence of F-specific CD8 effector T cells in the lungs of both ΔF/TriAdj(polyI : C)- and ΔF/TriAdj(CpG)-immunized mice. Both ΔF/TriAdj formulations induced RSV-specific CD8 T cells. However, ΔF/TriAdj(polyI : C) generated significantly higher IgG affinity maturation and higher numbers of RSV-specific CD8 effector memory T cells in lungs and CD8 central memory T cells in spleen and lymph nodes than ΔF/TriAdj(CpG). After RSV challenge, no virus replication and no evidence of vaccine-induced pathology were detected in mice immunized with either of the ΔF/TriAdj formulations, demonstrating that the duration of immunity induced with these vaccines is at least one year.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.062570-0
2014-05-01
2020-01-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/5/1043.html?itemId=/content/journal/jgv/10.1099/vir.0.062570-0&mimeType=html&fmt=ahah

References

  1. Aeffner F. , Traylor Z. P. , Yu E. N. , Davis I. C. . ( 2011; ). Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. . Am J Physiol Lung Cell Mol Physiol 301:, L99–L109. [CrossRef] [PubMed]
    [Google Scholar]
  2. Andrianov A. K. , DeCollibus D. P. , Gillis H. A. , Kha H. H. , Marin A. , Prausnitz M. R. , Babiuk L. A. , Townsend H. , Mutwiri G. . ( 2009; ). Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. . Proc Natl Acad Sci U S A 106:, 18936–18941. [CrossRef] [PubMed]
    [Google Scholar]
  3. Bevan M. J. . ( 2011; ). Understand memory, design better vaccines. . Nat Immunol 12:, 463–465. [CrossRef] [PubMed]
    [Google Scholar]
  4. Boukhvalova M. S. , Sotomayor T. B. , Point R. C. , Pletneva L. M. , Prince G. A. , Blanco J. C. . ( 2010; ). Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. . J Interferon Cytokine Res 30:, 229–242. [CrossRef] [PubMed]
    [Google Scholar]
  5. Butowski N. , Chang S. M. , Junck L. , DeAngelis L. M. , Abrey L. , Fink K. , Cloughesy T. , Lamborn K. R. , Salazar A. M. , Prados M. D. . ( 2009; ). A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). . J Neurooncol 91:, 175–182. [CrossRef] [PubMed]
    [Google Scholar]
  6. Castiglioni P. , Gerloni M. , Zanetti M. . ( 2004; ). Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. . Vaccine 23:, 699–708. [CrossRef] [PubMed]
    [Google Scholar]
  7. Collins P. L. , Graham B. S. . ( 2008; ). Viral and host factors in human respiratory syncytial virus pathogenesis. . J Virol 82:, 2040–2055. [CrossRef] [PubMed]
    [Google Scholar]
  8. Connors M. , Collins P. L. , Firestone C. Y. , Murphy B. R. . ( 1991; ). Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. . J Virol 65:, 1634–1637.[PubMed]
    [Google Scholar]
  9. Cooper C. L. , Davis H. L. , Morris M. L. , Efler S. M. , Krieg A. M. , Li Y. , Laframboise C. , Al Adhami M. J. , Khaliq Y. . & other authors ( 2004; ). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. . Vaccine 22:, 3136–3143. [CrossRef] [PubMed]
    [Google Scholar]
  10. Cooper C. L. , Angel J. B. , Seguin I. , Davis H. L. , Cameron D. W. . ( 2008; ). CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. . Clin Infect Dis 46:, 1310–1314. [CrossRef] [PubMed]
    [Google Scholar]
  11. Delgado M. F. , Coviello S. , Monsalvo A. C. , Melendi G. A. , Hernandez J. Z. , Batalle J. P. , Diaz L. , Trento A. , Chang H. Y. . & other authors ( 2009; ). Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. . Nat Med 15:, 34–41. [CrossRef] [PubMed]
    [Google Scholar]
  12. Ewel C. H. , Urba W. J. , Kopp W. C. , Smith J. W. II , Steis R. G. , Rossio J. L. , Longo D. L. , Jones M. J. , Alvord W. G. . & other authors ( 1992; ). Polyinosinic-polycytidylic acid complexed with poly-l-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. . Cancer Res 52:, 3005–3010.[PubMed]
    [Google Scholar]
  13. Falsey A. R. , Hennessey P. A. , Formica M. A. , Cox C. , Walsh E. E. . ( 2005; ). Respiratory syncytial virus infection in elderly and high-risk adults. . N Engl J Med 352:, 1749–1759. [CrossRef] [PubMed]
    [Google Scholar]
  14. Garg R. , Latimer L. , Simko E. , Gerdts V. , Potter A. , van den Hurk S. . ( 2014; ). Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. . J Gen Virol 95:, 301–306. [CrossRef] [PubMed]
    [Google Scholar]
  15. Garlapati S. , Garg R. , Brownlie R. , Latimer L. , Simko E. , Hancock R. E. W. , Babiuk L. A. , Gerdts V. , Potter A. , van Drunen Littel-van den Hurk S. . ( 2012; ). Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. . Vaccine 30:, 5206–5214. [CrossRef] [PubMed]
    [Google Scholar]
  16. Graham B. S. . ( 2011; ). Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. . Immunol Rev 239:, 149–166. [CrossRef] [PubMed]
    [Google Scholar]
  17. Hall C. B. . ( 2001; ). Respiratory syncytial virus and parainfluenza virus. . N Engl J Med 344:, 1917–1928. [CrossRef] [PubMed]
    [Google Scholar]
  18. Hancock G. E. , Heers K. M. , Smith J. D. , Scheuer C. A. , Ibraghimov A. R. , Pryharski K. S. . ( 2001; ). CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). . Vaccine 19:, 4874–4882. [CrossRef] [PubMed]
    [Google Scholar]
  19. Hornung V. , Rothenfusser S. , Britsch S. , Krug A. , Jahrsdörfer B. , Giese T. , Endres S. , Hartmann G. . ( 2002; ). Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. . J Immunol 168:, 4531–4537.[PubMed] [CrossRef]
    [Google Scholar]
  20. Ichinohe T. , Watanabe I. , Ito S. , Fujii H. , Moriyama M. , Tamura S. , Takahashi H. , Sawa H. , Chiba J. . & other authors ( 2005; ). Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. . J Virol 79:, 2910–2919. [CrossRef] [PubMed]
    [Google Scholar]
  21. Ichinohe T. , Kawaguchi A. , Tamura S. , Takahashi H. , Sawa H. , Ninomiya A. , Imai M. , Itamura S. , Odagiri T. . & other authors ( 2007; ). Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. . Microbes Infect 9:, 1333–1340. [CrossRef] [PubMed]
    [Google Scholar]
  22. Ichinohe T. , Ainai A. , Ami Y. , Nagata N. , Iwata N. , Kawaguchi A. , Suzaki Y. , Odagiri T. , Tashiro M. . & other authors ( 2010; ). Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. . J Med Virol 82:, 1754–1761. [CrossRef] [PubMed]
    [Google Scholar]
  23. Ioannou X. P. , Gomis S. M. , Karvonen B. , Hecker R. , Babiuk L. A. , van Drunen Littel-van den Hurk S. . ( 2002; ). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. . Vaccine 21:, 127–137. [CrossRef] [PubMed]
    [Google Scholar]
  24. Johnson J. E. , Gonzales R. A. , Olson S. J. , Wright P. F. , Graham B. S. . ( 2007; ). The histopathology of fatal untreated human respiratory syncytial virus infection. . Mod Pathol 20:, 108–119. [CrossRef] [PubMed]
    [Google Scholar]
  25. Kim H. W. , Canchola J. G. , Brandt C. D. , Pyles G. , Chanock R. M. , Jensen K. , Parrott R. H. . ( 1969; ). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. . Am J Epidemiol 89:, 422–434.[PubMed]
    [Google Scholar]
  26. Kovacs-Nolan J. , Latimer L. , Landi A. , Jenssen H. , Hancock R. E. , Babiuk L. A. , van Drunen Littel-van den Hurk S. . ( 2009; ). The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. . Vaccine 27:, 2055–2064. [CrossRef] [PubMed]
    [Google Scholar]
  27. Krieg A. M. . ( 2002; ). CpG motifs in bacterial DNA and their immune effects. . Annu Rev Immunol 20:, 709–760. [CrossRef] [PubMed]
    [Google Scholar]
  28. Kumar M. , Behera A. K. , Matsuse H. , Lockey R. F. , Mohapatra S. S. . ( 1999; ). Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection. . Vaccine 18:, 558–567. [CrossRef] [PubMed]
    [Google Scholar]
  29. Lampkin B. C. , Levine A. S. , Levy H. , Krivit W. , Hammond D. . ( 1985; ). Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-l-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children’s Cancer Study Group. . Cancer Res 45:, 5904–5909.[PubMed]
    [Google Scholar]
  30. Le Bon A. , Durand V. , Kamphuis E. , Thompson C. , Bulfone-Paus S. , Rossmann C. , Kalinke U. , Tough D. F. . ( 2006; ). Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. . J Immunol 176:, 4682–4689.[PubMed] [CrossRef]
    [Google Scholar]
  31. Lee F. E. , Walsh E. E. , Falsey A. R. , Lumb M. E. , Okam N. V. , Liu N. , Divekar A. A. , Hall C. B. , Mosmann T. R. . ( 2007; ). Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection. . J Infect Dis 195:, 1779–1788. [CrossRef] [PubMed]
    [Google Scholar]
  32. Mapletoft J. W. , Oumouna M. , Kovacs-Nolan J. , Latimer L. , Mutwiri G. , Babiuk L. A. , van Drunen Littel-van den Hurk S. . ( 2008; ). Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. . J Gen Virol 89:, 250–260. [CrossRef] [PubMed]
    [Google Scholar]
  33. Matsumoto M. , Seya T. . ( 2008; ). TLR3: interferon induction by double-stranded RNA including poly(I:C). . Adv Drug Deliv Rev 60:, 805–812. [CrossRef] [PubMed]
    [Google Scholar]
  34. McFarlin D. E. , Bever C. T. , Salazar A. M. , Levy H. B. . ( 1985; ). A preliminary trial of poly(I,C)-LC in multiple sclerosis. . J Biol Response Mod 4:, 544–548.[PubMed]
    [Google Scholar]
  35. Minne A. , Louahed J. , Mehauden S. , Baras B. , Renauld J.-C. , Vanbever R. . ( 2007; ). The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. . Immunology 122:, 316–325. [CrossRef] [PubMed]
    [Google Scholar]
  36. Mookherjee N. , Wilson H. L. , Doria S. , Popowych Y. , Falsafi R. , Yu J. J. , Li Y. , Veatch S. , Roche F. M. . & other authors ( 2006; ). Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. . J Leukoc Biol 80:, 1563–1574. [CrossRef] [PubMed]
    [Google Scholar]
  37. Nordlund J. J. , Wolff S. M. , Levy H. B. . ( 1970; ). Inhibition of biologic activity of poly I: poly C by human plasma. . Proc Soc Exp Biol Med 133:, 439–444. [CrossRef] [PubMed]
    [Google Scholar]
  38. Power U. F. . ( 2008; ). Respiratory syncytial virus (RSV) vaccines–two steps back for one leap forward. . J Clin Virol 41:, 38–44. [CrossRef] [PubMed]
    [Google Scholar]
  39. Prince G. A. , Mond J. J. , Porter D. D. , Yim K. C. , Lan S. J. , Klinman D. M. . ( 2003; ). Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. . J Virol 77:, 13156–13160. [CrossRef] [PubMed]
    [Google Scholar]
  40. Pulendran B. , Ahmed R. . ( 2011; ). Immunological mechanisms of vaccination. . Nat Immunol 12:, 509–517. [CrossRef] [PubMed]
    [Google Scholar]
  41. Robinson R. A. , DeVita V. T. , Levy H. B. , Baron S. , Hubbard S. P. , Levine A. S. . ( 1976; ). A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. . J Natl Cancer Inst 57:, 599–602.[PubMed]
    [Google Scholar]
  42. Rothenfusser S. , Tuma E. , Endres S. , Hartmann G. . ( 2002; ). Plasmacytoid dendritic cells: the key to CpG. . Hum Immunol 63:, 1111–1119. [CrossRef] [PubMed]
    [Google Scholar]
  43. Sagara I. , Ellis R. D. , Dicko A. , Niambele M. B. , Kamate B. , Guindo O. , Sissoko M. S. , Fay M. P. , Guindo M. A. . & other authors ( 2009; ). A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. . Vaccine 27:, 7292–7298. [CrossRef] [PubMed]
    [Google Scholar]
  44. Salazar A. M. , Levy H. B. , Ondra S. , Kende M. , Scherokman B. , Brown D. , Mena H. , Martin N. , Schwab K. . & other authors ( 1996; ). Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. . Neurosurgery 38:, 1096–1103, discussion 1103–1104.[PubMed]
    [Google Scholar]
  45. Salk J. , Salk D. . ( 1977; ). Control of influenza and poliomyelitis with killed virus vaccines. . Science 195:, 834–847. [CrossRef] [PubMed]
    [Google Scholar]
  46. Schmidt M. R. , McGinnes L. W. , Kenward S. A. , Willems K. N. , Woodland R. T. , Morrison T. G. . ( 2012; ). Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. . J Virol 86:, 11654–11662. [CrossRef] [PubMed]
    [Google Scholar]
  47. Southam D. S. , Dolovich M. , O’Byrne P. M. , Inman M. D. . ( 2002; ). Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. . Am J Physiol Lung Cell Mol Physiol 282:, L833–L839.[PubMed] [CrossRef]
    [Google Scholar]
  48. Stahl-Hennig C. , Eisenblätter M. , Jasny E. , Rzehak T. , Tenner-Racz K. , Trumpfheller C. , Salazar A. M. , Uberla K. , Nieto K. . & other authors ( 2009; ). Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. . PLoS Pathog 5:, e1000373. [CrossRef] [PubMed]
    [Google Scholar]
  49. Stowell N. C. , Seideman J. , Raymond H. A. , Smalley K. A. , Lamb R. J. , Egenolf D. D. , Bugelski P. J. , Murray L. A. , Marsters P. A. . & other authors ( 2009; ). Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. . Respir Res 10:, 43. [CrossRef] [PubMed]
    [Google Scholar]
  50. The IMpact–RSV Study Group . ( 1998; ). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. . Pediatrics 102:, 531–537. [CrossRef]
    [Google Scholar]
  51. Thompson K. A. , Strayer D. R. , Salvato P. D. , Thompson C. E. , Klimas N. , Molavi A. , Hamill A. K. , Zheng Z. , Ventura D. , Carter W. A. . ( 1996; ). Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. . Eur J Clin Microbiol Infect Dis 15:, 580–587. [CrossRef] [PubMed]
    [Google Scholar]
  52. Trumpfheller C. , Caskey M. , Nchinda G. , Longhi M. P. , Mizenina O. , Huang Y. , Schlesinger S. J. , Colonna M. , Steinman R. M. . ( 2008; ). The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. . Proc Natl Acad Sci U S A 105:, 2574–2579. [CrossRef] [PubMed]
    [Google Scholar]
  53. Trumpfheller C. , Longhi M. P. , Caskey M. , Idoyaga J. , Bozzacco L. , Keler T. , Schlesinger S. J. , Steinman R. M. . ( 2012; ). Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. . J Intern Med 271:, 183–192. [CrossRef] [PubMed]
    [Google Scholar]
  54. Vaux-Peretz F. , Chapsal J. M. , Meignier B. . ( 1992; ). Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. . Vaccine 10:, 113–118. [CrossRef] [PubMed]
    [Google Scholar]
  55. Vujanic A. , Sutton P. , Snibson K. J. , Yen H.-H. , Scheerlinck J.-P. Y. . ( 2012; ). Mucosal vaccination: lung versus nose. . Vet Immunol Immunopathol 148:, 172–177. [CrossRef] [PubMed]
    [Google Scholar]
  56. Welliver T. P. , Garofalo R. P. , Hosakote Y. , Hintz K. H. , Avendano L. , Sanchez K. , Velozo L. , Jafri H. , Chavez-Bueno S. . & other authors ( 2007; ). Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. . J Infect Dis 195:, 1126–1136. [CrossRef] [PubMed]
    [Google Scholar]
  57. Wherry E. J. , Teichgräber V. , Becker T. C. , Masopust D. , Kaech S. M. , Antia R. , von Andrian U. H. , Ahmed R. . ( 2003; ). Lineage relationship and protective immunity of memory CD8 T cell subsets. . Nat Immunol 4:, 225–234. [CrossRef] [PubMed]
    [Google Scholar]
  58. Wiley J. A. , Hogan R. J. , Woodland D. L. , Harmsen A. G. . ( 2001; ). Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. . J Immunol 167:, 3293–3299.[PubMed] [CrossRef]
    [Google Scholar]
  59. Yeung A. T. Y. , Gellatly S. L. , Hancock R. E. W. . ( 2011; ). Multifunctional cationic host defence peptides and their clinical applications. . Cell Mol Life Sci 68:, 2161–2176. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.062570-0
Loading
/content/journal/jgv/10.1099/vir.0.062570-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error